Business
ADOCIA Announces its Financial Calendar for 2026
LYON, France, December 18, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.
About this update from Adocia Sa
LYON, France, December 18, 2025 --( BUSINESS WIRE )--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026. In addition to regular meetings with the financial community, investors can also find updated information on the company’s website ( www.adocia.com ). All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section " Regulated Information ". About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone ® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral ® , an oral peptide delivery technology; 3) AdoShell ® , an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong TM , a long-acting peptide platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241). View source version on businesswire.com: https://www.businesswire.com/news/home/20251218443649/en/ Contacts Adocia Olivier Soula CEO [email protected] +33 (0)4 72 610 610 www.adocia.com Ulysse Communication Adocia Press & Investor Relations Bruno Arabian Nicolas Entz [email protected] + 33 (0)6 87 88 47 26